8-K: FibroGen Announces Sale of China Operations to AstraZeneca and Reports Q4 and Full Year 2024 Financial Results

FibroGen reports the sale of its China operations to AstraZeneca for approximately $160 million and provides financial results for Q4 and full year 2024, highlighting a cost reduction plan and a focus on its ADC program.

Summary

• FibroGen announced the sale of FibroGen China to AstraZeneca for approximately $160 million, expected to close by mid-2025.
• Upon closing of the sale, FibroGen expects to extend its cash runway into 2027 and repay its term loan to Morgan Stanley Tactical Value.
• The company plans to initiate a Phase 2 monotherapy trial of FG-3246, an ADC targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), by mid-2025.
• Topline results from a Phase 2 portion of an investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC are expected in the second half of 2025.
• Total revenue from continuing operations for Q4 2024 was $3.1 million, compared to $3.6 million for Q4 2023.
• Total revenue from continuing operations for the full year 2024 was $29.6 million, compared to $46.8 million for the full year 2023.
• Net loss from continuing operations for Q4 2024 was $8.7 million, or $0.08 net loss per share, compared to a net loss of $62.5 million, or $0.63 net loss per share, in the prior year.
• Net loss from continuing operations for the full year 2024 was $153.1 million, or $1.53 net loss per share, compared to a net loss of $323.0 million, or $3.32 net loss per share, for the full year 2023.
• As of December 31, 2024, FibroGen reported $51.0 million in cash, cash equivalents, and accounts receivable in the U.S. and $121.1 million in total consolidated cash, cash equivalents, and accounts receivable.
• FibroGen received a delisting notice from Nasdaq due to its stock price falling below $1.00, but has appealed the decision, staying the delisting.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the sale of FibroGen China, which improves the company's financial position. However, concerns remain regarding declining revenue, continued net losses, and the Nasdaq delisting notice.

Positives

• The sale of FibroGen China to AstraZeneca for $160 million will significantly improve FibroGen's financial position.
• The extended cash runway into 2027 provides financial stability for ongoing and planned clinical trials.
• The planned initiation of the Phase 2 monotherapy trial of FG-3246 represents progress in the company's oncology pipeline.
• The reduced net loss from continuing operations in 2024 compared to 2023 indicates improved cost management.
• The appeal of the Nasdaq delisting notice provides an opportunity for FibroGen to regain compliance and maintain its listing.

Negatives

• The decline in total revenue from continuing operations in 2024 compared to 2023 is a concern.
• The company continues to experience net losses from continuing operations.
• The receipt of a delisting notice from Nasdaq indicates financial challenges and investor concerns.
• The company is reliant on the closing of the sale of FibroGen China to AstraZeneca to extend its cash runway.

Risks

• The sale of FibroGen China to AstraZeneca may not close as expected.
• The company may not be successful in its appeal to the Nasdaq Hearings Panel.
• FibroGen may not regain compliance with the minimum bid price rule or maintain compliance with other listing requirements.
• Clinical trials of FG-3246 and roxadustat may not be successful.
• The company may face challenges in obtaining regulatory approval for roxadustat in the U.S. for anemia associated with LR-MDS.
• The company may need to raise additional capital in the future.

Future Outlook

FibroGen expects its cash, cash equivalents, and accounts receivable to be sufficient to fund operations into 2027 upon closing of the sale of FibroGen China. The company plans to initiate a Phase 2 monotherapy trial of FG-3246 in mCRPC by mid-2025 and expects topline results from a Phase 2 study of FG-3246 in combination with enzalutamide in mCRPC in the second half of 2025. FibroGen also plans to meet with the FDA in Q2 2025 to discuss the next steps for roxadustat development in anemia associated with LR-MDS in the U.S.

Management Comments

• We entered 2025 optimistic about our future, highlighted by the planned initiation of the Phase 2 monotherapy trial of FG-3246, our first-in-class ADC targeting CD46 for the treatment of mCRPC, by mid-2025, said Thane Wettig, Chief Executive Officer.
• Through the successful implementation of our cost reduction plan, and upon the closing of our recently announced sale of FibroGen China, we will be a leaner and more focused organization, with a stronger financial position and a cash runway that takes us into 2027, with multiple potential value-creating milestones in sight.

Industry Context

The sale of FibroGen's China operations to AstraZeneca reflects a trend of pharmaceutical companies streamlining their operations and focusing on core assets. The development of FG-3246, an ADC targeting CD46, aligns with the growing interest in targeted therapies for cancer. The continued development of roxadustat in anemia associated with LR-MDS addresses an unmet medical need in the hematology space.

Comparison to Industry Standards

• The $160 million sale of FibroGen China to AstraZeneca is a relatively small deal compared to other recent pharmaceutical acquisitions, but it is significant for FibroGen in terms of extending its cash runway.
• The development of FG-3246 as a potential first-in-class ADC targeting CD46 puts FibroGen in competition with other companies developing ADCs for cancer treatment, such as Seagen and Immunomedics (now part of Gilead).
• Roxadustat competes with other erythropoiesis-stimulating agents (ESAs) for the treatment of anemia, such as Amgen's Epogen and Aranesp, as well as newer HIF-PH inhibitors like GSK's daprodustat.

Management Changes

Stakeholder Impact

• Shareholders: The sale of FibroGen China and the potential for extended cash runway could be viewed positively, but concerns remain regarding the delisting notice and financial performance.
• Employees: The cost reduction program and sale of FibroGen China may result in job losses or restructuring.
• Customers: The continued development of roxadustat and FG-3246 could provide new treatment options for patients with anemia and mCRPC.
• Suppliers: The company's financial stability is important for maintaining relationships with suppliers.
• Creditors: The repayment of the term loan to Morgan Stanley Tactical Value will simplify the company's capital structure.

Next Steps

• Close the sale of FibroGen China to AstraZeneca by mid-2025.
• Repay the term loan to Morgan Stanley Tactical Value.
• Initiate the Phase 2 monotherapy trial of FG-3246 in mCRPC by mid-2025.
• Obtain topline results from the Phase 2 study of FG-3246 in combination with enzalutamide in mCRPC in the second half of 2025.
• Meet with the FDA in Q2 2025 to discuss the next steps for roxadustat development in anemia associated with LR-MDS in the U.S.
• Appeal the Nasdaq delisting determination and regain compliance with listing requirements.

Key Dates